Cohort study comparing prostate photovaporisation with XPS 180W and HPS 120W laser.
OBJECTIVE
Prostate photovaporisation with Greenlight laser for the surgical treatment of benign prostate hyperplasia has rapidly evolve to the new XPS 180W. We have previously demonstrated the safety and efficacy of the HPS 120W. The aim of this study was to assess the functional and safety results, with a year of follow-up, of photovaporisation using the XPS 180W laser compared with its predecessor.


METHODS
A cohort study was conducted with a series of 191 consecutive patients who underwent photovaporisation between 1/2008 and 5/2013. The inclusion criteria were an international prostate symptom score (IPSS) >15 after medical failure, a prostate volume <80 cm(3) and a maximum flow <15 mL/s. We assessed preoperative and intraoperative variables (energy used, laser time and total surgical time), complications, catheter hours, length of stay and functional results (maximum flow, IPSS, prostate-specific antigen and prostate volume) at 3, 6 and 12 months. We analysed the homogeneity in preoperative characteristics of the 2 groups through univariate analysis techniques. The postoperative functional results were assessed through an analysis of variance of repeated measures with mixed models.


RESULTS
A total of 109 (57.1%) procedures were performed using HPS 120W, and 82 (42.9%) were performed using XPS. There were no differences between the preoperative characteristics. We observed significant differences both in the surgical time and effective laser time in favour of the XPS system. This advantage was 11% (48 ± 15.7 vs. 53.8 ± 16.2, p<.05) and 9% (32.8 ± 11.7 vs. 36 ± 11.6, p<.05), respectively. There were no statistically significant differences in the rest of the analysed parameters.


CONCLUSIONS
The technical improvements in the XPS 180W system help reduce surgical time, maintaining the safety and efficacy profile offered by the HPS 120W system, with completely superimposable results at 1 year of follow-up.
Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, España. Electronic address: blopezl@hotmail.com.
B
B
López
Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, España.
C
C
Capitán
Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, España.
V
V
Hernández
Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, España.
E
E
de la Peña
Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, España.
I
I
Jiménez-Valladolid
Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, España.
A
A
Guijarro
Unidad de Investigación, Hospital Universitario Fundación Alcorcón, Madrid, España.
E
E
Pérez-Fernández
Servicio de Urología, Hospital Universitario Fundación Alcorcón, Madrid, España.
C
C
Llorente
D000368:Aged; D015331:Cohort Studies; D006801:Humans; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D011470:Prostatic Hyperplasia / Q000601:surgery*; D020728:Transurethral Resection of Prostate / Q000379:methods*; D016896:Treatment Outcome
Benign prostate hyperplasia; Fotovaporización prostática; Greenlight laser; Hiperplasia benigna de próstata; Lower urinary tract symptoms; Láser Greenlight; Prostate photovaporisation; Sintomatología del tracto urinario inferior